238 related articles for article (PubMed ID: 37342346)
21. The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus.
Sari S; Cinar S; Yalcinkaya Y; Artim-Esen B; Ozluk Y; Gul A; Ocal L; Deniz G; Inanc M
Lupus; 2022 Apr; 31(5):555-564. PubMed ID: 35249405
[TBL] [Abstract][Full Text] [Related]
22. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.
Scheinberg MA; Hislop CM; Martin RS
Expert Opin Biol Ther; 2016; 16(5):723-33. PubMed ID: 27051973
[TBL] [Abstract][Full Text] [Related]
23. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
24. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.
Zhao LD; Li Y; Smith MF; Wang JS; Zhang W; Tang FL; Tian XP; Wang HY; Zhang FC; Ba DN; He W; Zhang X
Lupus; 2010 Nov; 19(13):1534-49. PubMed ID: 20974656
[TBL] [Abstract][Full Text] [Related]
25. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
[TBL] [Abstract][Full Text] [Related]
26. Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Hoi AY; Slavin L; Godsell JD; Kitching AR; Harris J; Nelson CL; Jenkins AJ; Chrysostomou A; Hibbs ML; Kerr PG; Rischmueller M; Mackay F; Morand EF
Lupus; 2018 Nov; 27(13):2029-2040. PubMed ID: 30301439
[TBL] [Abstract][Full Text] [Related]
27. IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.
Liu Z; Bethunaickan R; Huang W; Ramanujam M; Madaio MP; Davidson A
J Immunol; 2011 Aug; 187(3):1506-13. PubMed ID: 21705616
[TBL] [Abstract][Full Text] [Related]
28. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
29. [Advances of using antibody against B cell activating factor for treatment of autoimmune diseases].
Lin R; Chen Y; Jin T; Cao M
Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):903-914. PubMed ID: 35355463
[TBL] [Abstract][Full Text] [Related]
30. Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice.
Ding H; Wang L; Wu X; Yan J; He Y; Ni B; Gao W; Zhong X
J Cell Mol Med; 2010 Jun; 14(6B):1717-25. PubMed ID: 19627403
[TBL] [Abstract][Full Text] [Related]
31. The Roles of Systemic Lupus Erythematosus and Immunoglobulin A Nephropathy in Glomerular Disease.
Browning SG
Nurs Clin North Am; 2018 Dec; 53(4):531-539. PubMed ID: 30388979
[TBL] [Abstract][Full Text] [Related]
32. The role of BAFF and APRIL in rheumatoid arthritis.
Shabgah AG; Shariati-Sarabi Z; Tavakkol-Afshari J; Mohammadi M
J Cell Physiol; 2019 Aug; 234(10):17050-17063. PubMed ID: 30941763
[TBL] [Abstract][Full Text] [Related]
33. [B lymphocyte stimulator in systemic lupus erythematosus].
Mercado U
Rev Med Inst Mex Seguro Soc; 2012; 50(4):349-50. PubMed ID: 23234733
[TBL] [Abstract][Full Text] [Related]
34. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice.
Ramanujam M; Bethunaickan R; Huang W; Tao H; Madaio MP; Davidson A
Arthritis Rheum; 2010 May; 62(5):1457-68. PubMed ID: 20131293
[TBL] [Abstract][Full Text] [Related]
35. A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice.
Yu C; Chen S; Zhou B; Zhang H; Su X; Luo Y; Yang L
Mol Immunol; 2021 Jan; 129():1-11. PubMed ID: 33254074
[TBL] [Abstract][Full Text] [Related]
36. The BAFF / APRIL system as therapeutic target in multiple sclerosis.
Magliozzi R; Marastoni D; Calabrese M
Expert Opin Ther Targets; 2020 Nov; 24(11):1135-1145. PubMed ID: 32900236
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.
Friebus-Kardash J; Trendelenburg M; Eisenberger U; Ribi C; Chizzolini C; Huynh-Do U; Lang KS; Wilde B; Kribben A; Witzke O; Dolff S; Hardt C
BMC Nephrol; 2019 Nov; 20(1):430. PubMed ID: 31752784
[TBL] [Abstract][Full Text] [Related]
38. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
39. Abnormal expression of BAFF and its receptors in peripheral blood and skin lesions from systemic lupus erythematosus patients.
Chen Y; Yang M; Long D; Li Q; Zhao M; Wu H; Lu Q
Autoimmunity; 2020 Jun; 53(4):192-200. PubMed ID: 32157911
[TBL] [Abstract][Full Text] [Related]
40. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus.
Eilertsen GØ; Nossent JC
Lupus; 2014 Nov; 23(13):1383-91. PubMed ID: 25057039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
